iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLLMichael Hallek, Thomas J. Kipps, Bruce D. Cheson et al.|Blood|2018Cited by 1.7k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid LeukemiaJohn C. Byrd, Peter Hillmen, Tadeusz Robak et al.|New England Journal of Medicine|2014Cited by 1.6k
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic LeukemiaJan A. Burger, Thomas J. Kipps, Alessandra Tedeschi et al.|New England Journal of Medicine|2015Cited by 1.6k
Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic LeukemiaJohn F. Seymour, Arnon P. Kater, Thomas J. Kipps et al.|New England Journal of Medicine|2018Cited by 907
Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III TrialJohn C. Byrd, Wojciech Jurczak, Peter Hillmen et al.|Journal of Clinical Oncology|2021Cited by 630